SCHEMBL2553992

SCHEMBL2553992

COc1cc(C=CC(=O)O)ccc1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.69
ALDH1A1 P00352 3/20 0.69
HPGD P15428 2/20 0.69
HSD17B10 Q99714 2/20 0.69
ALOX15 P16050 1/20 0.69
MAPK1 P28482 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
SNCA P37840 2/20 0.58
PKM P14618 2/20 0.58
CA12 O43570 1/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA3 P07451 1/20 0.58
CSNK2A2 P19784 1/20 0.58
CA4 P22748 1/20 0.58
CA6 P23280 1/20 0.58
CA5A P35218 1/20 0.58
CA7 P43166 1/20 0.58
CSNK2B P67870 1/20 0.58
CSNK2A1 P68400 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2553988 1.00 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL30656553 1.00 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL2408521 0.93 KDM4E (0.57) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL2408525 0.93 KDM4E (0.57) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL23805172 0.91 KDM4E (0.57) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL14342653 0.90 FDPS (0.61) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL9553571 0.90 FDPS (0.61) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL17529412 0.88 KMT2A (0.56) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL22770082 0.88 KDM4E (0.57) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL23665036 0.87 KMT2A (0.54) KDM4EALDH1A1HPGDHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2925755-B1 NEUROPROTECTIVE AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES UNIV WAYNE STATE (US) 2021-09-08 EP disclosed
US-10874669-B2 Neuroprotective agents for treatment of neurodegenerative diseases WAYNE STATE UNIVERSITY (US) 2020-12-29 US disclosed
US-20190076426-A1 NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES WAYNE STATE UNIVERSITY 2019-03-14 US disclosed
US-20190038622-A1 NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES WAYNE STATE UNIVERSITY 2019-02-07 US disclosed
US-10125127-B2 Neuroprotective agents for treatment of neurodegenerative diseases WAYNE STATE UNIVERSITY (US) 2018-11-13 US disclosed
US-20150299180-A1 NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES WAYNE STATE UNIVERSITY (US) 2015-10-22 US disclosed
US-8637674-B2 Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2014-01-28 US disclosed
EP-2556062-A1 AMIDE DERIVATIVES OF CINNAMIC, FERULIC AND AVENALUMIC SERIES, PROCESS FOR PREPARING SAME AND COSMETIC COMPOSITIONS CONTAINING SAME Produits Chimiques Auxiliaires et de Synthese (FR) 2013-02-13 EP disclosed
US-20120232117-A1 PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2012-09-13 US disclosed
WO-2011124844-A1 AMIDE DERIVATIVES OF CINNAMIC, FERULIC AND AVENALUMIC SERIES, PROCESS FOR PREPARING SAME AND COSMETIC COMPOSITIONS CONTAINING SAME PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) 2011-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299180-A1 NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES RTN4, NR4A1, NR4A3 KDM4E 1641/4885ALDH1A1 1123/4885HPGD 1787/4885
US-20190076426-A1 NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES SMN1; SMN2, PARK7, SNCA KDM4E 3307/4885ALDH1A1 1481/4885HPGD 1216/4885
US-20190038622-A1 NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES SMN1; SMN2, PARK7, SNCA KDM4E 3307/4885ALDH1A1 1481/4885HPGD 1216/4885
US-10125127-B2 Neuroprotective agents for treatment of neurodegenerative diseases RTN4, NR4A1, NR4A3 KDM4E 1641/4885ALDH1A1 1123/4885HPGD 1787/4885
US-10874669-B2 Neuroprotective agents for treatment of neurodegenerative diseases SMN1; SMN2, PARK7, SNCA KDM4E 3307/4885ALDH1A1 1481/4885HPGD 1216/4885
US-20120232117-A1 PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME PTH1R, VDR, SOST KDM4E 1561/4885ALDH1A1 2869/4885HPGD 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.